Compare SABS & FUBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SABS | FUBO |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | 86 | 590 |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.8M | 265.1M |
| IPO Year | N/A | 2011 |
| Metric | SABS | FUBO |
|---|---|---|
| Price | $3.89 | $9.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $10.75 | ★ $20.33 |
| AVG Volume (30 Days) | 491.5K | ★ 1.6M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,271,000.00 |
| Revenue This Year | N/A | $44.64 |
| Revenue Next Year | N/A | $5.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10317.07 |
| 52 Week Low | $1.85 | $1.02 |
| 52 Week High | $5.15 | $14.54 |
| Indicator | SABS | FUBO |
|---|---|---|
| Relative Strength Index (RSI) | 58.53 | 46.94 |
| Support Level | $3.68 | $8.54 |
| Resistance Level | $4.10 | $10.69 |
| Average True Range (ATR) | 0.19 | 0.69 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 80.65 | 28.93 |
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
FuboTV Inc is a sports-first, Pay TV replacement product offering subscribers access to tens of thousands of live sporting events annually, alongside news and entertainment content, both live and on demand. Its platform is designed to empower customers to seamlessly access content through streaming devices and on Smart TVs, mobile phones, tablets, and computers. The company offers subscribers a live TV streaming service with the option to purchase incremental features, including additional content or enhanced functionality suited to their preferences. Its subscription packages (including Fubo Essential, Pro, Elite, and others) boast a broad mix of top Nielsen-ranked channels across sports, news, and entertainment. The company operates in a single segment of the streaming business.